Drugs / TNG260
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05887492 | Jun 2023 → Sep 2026 overdue | lung adenocarcinoma | Tango Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNG260 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05887492 ↗ |
| Action | Inhibit | “CoREST inhibitor” NCT05887492 ↗ |
| Route | Oral | “administered orally” NCT05887492 ↗ |